期刊文献+

应用骨靶向药物治疗骨质疏松症的研究进展 被引量:8

原文传递
导出
摘要 目的:综述骨靶向药物治疗骨质疏松症的应用状况。方法:根据查阅相关文献及临床实践经验。结果:目前上市的骨质疏松治疗药物对患者都有一定效果,但尚有缺陷和使用上的限制。结论:寻找结构稳定,趋骨性强的载体化合物是研究骨靶向药物的重要环节。目前研究最多的双磷酸类及四环素类除具有亲骨性外,本身对骨也有一定作用,作为骨靶向性载体将会受到进一步关注。
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2010年第3期234-236,共3页 Chinese Journal of Hospital Pharmacy
基金 国家自然科学基金项目(编号:30901522)
  • 相关文献

参考文献15

  • 1Sipos W, Pietschmann P, Rauner M, et al. Pathophysiology of osteoporosis[J].Wien Med Wochenschr, 2009, 159 (9-10) : 230-234.
  • 2苏畅,梁林,李楠,李灵芝.骨靶向化合物研究进展[J].武警医学院学报,2007,16(2):205-208. 被引量:4
  • 3Zheng Hu, Weng I.ingling. Bone resorption inhibition/osteogenesis promotion pharmaceutical composition[P]. US Patent 5698542. 1997/12/16-2015/08/29.
  • 4卢飙,孙晓村,贺颖,陈槐卿,翁玲玲,郑虎,邱明才.四环素-雌酮对去卵巢山羊髂骨的有利作用[J].中华内分泌代谢杂志,2004,20(1):75-78. 被引量:1
  • 5Bentz H, Rosen D. Conjugated for targeted, delivery of bone growth fac:ors[P]. Eur Pat: 512844,1992-11-11.
  • 6Orme MW, Labroo VM. Synthesis of α-estradilol-3-benzoate- 17-(succinyl-12 α-tetracycline. ) : a potential boneseeking estrogen[J].Bioorg Med Chem lett, 1994 ( 11 ): 1275-1380.
  • 7Takahashi-Nishioka T, Yokogawa K, Tomatsu S, et al. Targeted drug delivery to bone: pharmacokinetic and pharmacological properlies of acidic oligopeptide tagged drugs[J].Curr Drug Discov Technol,2008,5( 1 ) :39-48.
  • 8Neale JR,Richter NB, Merten KE, et al. Bone selective effect of an estradiol conjugate with a novel tetracycline dcrived bone targeting agent[J]. Bioorg Med Chem Lett, 2009, 19 (3) : 680- 683.
  • 9Hohnes SG, Still K, Buttle DJ, et al. Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precu rsors[J].Bone, 2004,35 (2) : 471-478.
  • 10张德志,胡蕴玉,范宏斌,吕荣,王军,孟国林,李丹.骨靶向药物四环素预防激素增强Shwartzman反应骨坏死的实验研究[J].国际内分泌代谢杂志,2006,26(1):60-62. 被引量:1

二级参考文献58

  • 1Bauss F, Esswein A, Reiff K, et al. Effect of 17beta-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17beta-estradiol serum kinetics and bone mass in rats[J]. Calcif Tissue Int, 1996, 59(3):168-173.
  • 2Hirabayashi H, Takahashi T, Fujisaki J, et al. Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS)[J]. J Controlled Release, 2001, 70(1-2):183-191.
  • 3Fujisaki J, Tokunaga Y, Takahashi T, et al. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I.V. effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats[J]. J Drug Target, 1998, 5:129-138.
  • 4Fujisaki J, Tokunaga Y, Takahashi T,et al. Osteotropic drug delivery system(ODDS) based on bisphosphonic prodrug. V. biological disposition and targeting characteristics of osteotropic estradiol[J]. Biol Pharm Bull, 1997, 20(11):1183-1187.
  • 5Fujisaki J, Tokunaga Y, Takahashi T,et al. Physicochemical characterization of bisphosphonic carboxyfluorescein for osteotropic drug delivery[J]. J Pharm Pharmacol, 1996, 48:798-800.
  • 6Page P C B, Moore J P G, Manfield I, et al. Synthesis of bone-targeted oestrogenic compounds for the inhibition of bone resorption[J]. Tetrahedron, 2001, 57:1837-1847.
  • 7Page P C B, McKenzie M J, Gallagher J A, Novel synthesis of bis(phosphonic acid)-steroid conjugates[J]. J Org Chem, 2001, 66:3704-3708.
  • 8Sugioka T, MizuhoInazu S. Bisphosphonate derivative [P]. US:5428181, 1995-07-27.
  • 9Saari W S, Rodan G A, Fisher T E, et al. Bone acting agents[P]. US: 5183815, 1993-02-02.
  • 10Kadowaki S, Mori A, Kamizono A, et al. Steroid derivatives[P]. EP: 0555845, 1993-08-18.

共引文献5

同被引文献127

引证文献8

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部